The global non-sterile liquids/suspensions market held a valuation of US$ 2.6 Billion in 2022, and it is further projected to expand at a CAGR of 6.5% over the forecasted years. According to a recent study by Future Market Insights, the oral dosage form is leading the market with a share of about 29.5% in the year 2022, within the global market.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 2.6 Billion |
| Market Value 2033 | US$ 5.2 Billion |
| CAGR 2023 to 2033 | 6.5% |
| Market Share of Top 5 Countries | 53.0% |
| Key Market Players | AbbVie Pharmaceutical Contract Manufacturing, Aenova Group, APPCO Pharmaceutical Corporation, Atral Pharmaceutical, Aurigene Pharmaceutical Services (Dr. Reddy’s), Biological E. Ltd., BioPlus Life Sciences, Bora Pharmaceuticals, Cambrex Corporation, COC Farmaceutici, Contract Pharmaceuticals Limited (CPL), DPT Laboratories, Ltd., Eurofins, JGL d.d., Mikart, PharmaVision (Vizyon Holding), Pierre Fabre, TriRx Pharmaceutical Services, UI Pharmaceuticals, Wasdell Group, Aphena Pharma, and Syngene International |
Active pharmaceutical ingredients (API) are dissolved in aqueous and non-aqueous solvents, suspended in suitable media, or incorporated into oil or water phases to create liquid dosage forms. As a result, there are many different formulations of pharmaceutical liquids. Liquids that are not sterile are prepared in settings that are clean but not entirely sterile. These non-sterile liquid pharmaceuticals can be applied internally or externally. An oral or topical route of drug administration can be used to provide a non-sterile liquid dose form. Moreover, liquid dosage forms provide advantages over other specialized dosage forms, including better patient compliance, quicker absorption, and more dosing flexibility.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global sales of the market are anticipated to rise at a CAGR of 6.5% between 2023 and 2033, owing to the various applications in a wide range of medication formulations. The demand for these products is increasing with respect to the pediatric and geriatric formulations and apart from this, the convenience and compliance provided by the products like mouth washes, gels, creams in reference to the way they are applied or consumed is something which fuels the growth of this market.
The global market holds around 7.3% share of the overall global solvent market with a value of around US$ 35.6 Billion, in 2022.
Non-sterile liquids/suspensions can be used to deliver a variety of medications, including prescription drugs, non-prescription drugs, vitamins, dietary supplements, and nutraceuticals. As the population ages, there is a growing demand for formulations that address the specific needs of the elderly. Pediatric formulations are also gaining traction, driven by the need for dosage forms that are easier to administer in children, example oral dosage forms. Pharmaceutical formulations, such as oral syrups, cough medicines, and other liquid drugs, frequently contain non-sterile liquids and suspensions. The demand for medicines may be influenced by the expanding access to healthcare in emerging nations, the rising prevalence of chronic diseases, and the expanding use of non-sterile fluids or suspensions.
It is also typical practice to produce nutraceuticals and nutritional supplements, such as vitamins, minerals, and botanical extracts, using non-sterile liquid or suspension formulations. The demand for non-sterile liquid or suspension formulations in this sector may rise as a result of rising consumer knowledge of the advantages of nutraceuticals and dietary supplements for health and wellness.
The aforementioned factors are expected to cause the global market to expand swiftly and reach an estimated value of US$ 5.2 Billion in 2033.
Due to ease of administration, better taste, and easier swallowing, many consumers, especially kids and elderly patients, may choose liquid formulations over solid dose forms like tablets or capsules. This can result in a rise in demand for non-sterile suspension or liquid formulations. This growing preference of liquid formulations would present lucrative opportunities for the market in the coming years.
Moreover, the creation of non-sterile liquids or suspensions with improved drug stability, bioavailability, and therapeutic efficacy may be made possible by the development of innovative drug delivery technologies like nanotechnology, liposomes, and microencapsulation. The market for non-sterile liquid or suspension formulations may be stimulated by these developments. In fact, companies today are utilizing cutting-edge technologies to improve both patient compliance and the bioavailability of dose forms.
Principal Consultant
Non-sterile liquid or suspension formulations may need to adhere to stringent regulatory criteria, such as those for quality assurance, safety, labeling, and manufacturing procedures. The market may be constrained by meeting these legal standards because they can be time-consuming and expensive, especially for startups or smaller firms.
Other than this, in comparison to solid dosage forms, non-sterile liquids or suspensions may have a shorter shelf life because they may be more prone to deterioration, microbial development, and other stability issues. This could shorten the shelf life of non-sterile liquid or suspension items, which might lead to product waste and higher expenditures for product expiry or recalls.
The USA dominated the North American region with market share of around 23.3% in the global market in 2022.
The USA market for non-sterile liquids/suspensions is driven by several factors, including the increasing demand for oral and topical dosage forms, the need for customized solutions that are designed for palatability and patient compliance, and the cost-effectiveness of non-sterile formulations compared to sterile formulations.
The USA market is characterized by a high level of innovation and technological advancement, which drives the development of new and improved non-sterile liquid/suspension formulations. The use of advanced technologies such as nanotechnology, microencapsulation, and spray drying can improve the stability, bioavailability, and efficacy of non-sterile liquid/suspension formulations.
Germany held a market share of 4.9% in 2022 in the global market. Non-sterile liquids/suspensions are frequently used to treat a variety of medical conditions such as cough, cold, allergies, and pain relief. The rising demand for OTC medications is propelling this market forward in this region.
With a focus on enhancing the patient experience and medication adherence, there is an increasing emphasis on patient-centric treatment in Germany. Non-sterile liquid or suspension formulations may have benefits for patients in terms of dosing flexibility, ease of administration, and patient convenience, all of which are consistent with patient-centric care paradigms.
The elderly population in Germany may have particular demands and preferences when it comes to the administration of medications. Older adults who may have trouble swallowing pills or capsules may prefer non-sterile liquid or suspension forms, which could increase demand for these formulations.
India had a market share of 8.8% in the global market in 2022. India's population is large and growing, which is driving demand for non-sterile liquids/suspensions. Chronic diseases such as diabetes, cardiovascular disease, and cancer are becoming more common in India. With a population of over 1.3 Billion people, India has a high demand for pharmaceutical products, including non-sterile liquids/suspensions. The increasing population and urbanization in India have led to a rise in the prevalence of diseases and health conditions, which has increased the demand for medications.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The oral dosage form held a market share of 29.5% in the global market in 2022.
For patients who might have trouble swallowing solid dosage forms like pills or capsules, non-sterile liquid or suspension formulations are frequently simple to administer. They are thus especially well-suited for certain patient groups, including kids, the elderly, and people who have trouble swallowing or who have other medical issues that make it difficult to take solid dosage forms. Many patients prefer liquid or suspension formulations due to their ease of use, convenience, and familiarity. This can contribute to the wide acceptance of oral dosage forms in the non-sterile liquid or suspensions market, as patient preference and convenience are important factors in medication selection and adherence.
The human medication segment held a market share of 40.1% in the global market in 2022. It is expected to expand due to technological advancements in disease diagnosis and treatment and increasing human populations with various acute diseases like acute pain and cold symptoms, and chronic diseases like cancer and diabetes. This further increases the adoption of pharmaceutical medicines.
Overall, the use of non-sterile liquids/suspensions in human medication offers advantages like enhanced bioavailability, rapid onset of action, improved medication adherence, and flexible dosing, thus driving the global market.
Pharmaceutical companies held a market share of 33.1% in the year 2022. Pharmaceutical companies are using more non-sterile liquids/suspensions in the production of medications due to the various advantages associated with formulations in human medications and veterinary medications. Pharmaceutical companies are taking non-sterile liquids/suspensions in bulk or package form for various applications like various dosage formulations with parenteral as well for rinsing of equipment. Apart from this, the rising number of pharmaceutical companies around the globe is another point as to which it dominates this segment.
Key players are focusing on agreements, mergers, partnerships, collaborations, and acquisitions as well as the introduction and commercialization of novel products and pharmaceuticals in order to broaden their clientele and raise business income. A few examples of strategies acquired by the key players:
Similarly, recent developments related to non-sterile liquids/suspensions market has been tracked by the team at Future Market Insights. These are available in the full report.
| Attribute | Details |
|---|---|
| Historical Data Available for | 2023 to 2033 |
| Forecast Period | 2012 to 2022 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, and the Middle East & Africa |
| Key Countries Covered | USA, Canada, Mexico, Brazil, Argentina, United Kingdom., Germany, Italy, Spain, France, Russia, Benelux, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Türkiye, GCC Countries, and South Africa |
| Key Market Segments Covered | Dosage Form, Application, End User, and Region |
| Key Companies Profiled |
|
| Pricing | Available upon Request |
From 2018 to 2022, the market registered a CAGR of 7.3%.
The market is estimated to reach US$ 5.2 billion by 2033.
Human medication hold high revenue potential.
The United States, Japan, and the United Kingdom dominate the global market.
The market is forecast to register a CAGR of 6.5% through 2033.
1. Executive Summary | Non-Sterile Liquids/Suspensions Market 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply-Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Value-Added Insights 4.1. Product Adoption / Usage Analysis, By Region 4.2. List of Key Contract Manufacturing Organizations (CMOs) and Contract Development & Manufacturing Organizations (CDMOs) 4.3. Porter’s analysis 4.4. PESTEL analysis 4.5. Key Regulations 4.6. Value Chain Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Industry Market Outlook 5.1.3. Global Pharmaceutical Water Market Outlook 5.2. Forecast Factors - Relevance & Impact 5.2.1. Growing Prevalence of Diseases 5.2.2. Growing Pediatric and Geriatric Population 5.2.3. Increase in Adoption Rate 5.2.4. Growth in Production Capacity 5.2.5. Sales Expansion 5.2.6. Quality Control Issues 5.2.7. Increasing Number of CMOs/CDMOs 5.2.8. Top Companies Historical Growth 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity 6. COVID-19 Crisis to Impact Assessment 6.1. COVID-19 and Impact Analysis 6.1.1. Revenue By Dosage Form 6.1.2. Revenue By Application 6.1.3. Revenue By End User 6.1.4. Revenue By Country 6.2. 2022 Scenario 7. Global Market Demand (in Value or Size in US$ Million) Analysis 2012 to 2022 and Forecast, 2023 to 2033 7.1. Historical Market Value (US$ Million) Analysis, 2012 to 2022 7.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Dosage Form 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) Analysis By Dosage Form, 2012 to 2022 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Dosage Form, 2023 to 2033 8.3.1. Oral 8.3.1.1. Mixtures 8.3.1.2. Linctures 8.3.1.3. Syrups 8.3.1.4. Elixirs 8.3.1.5. Mouth Washes/Gargles 8.3.1.6. Drops 8.3.2. Ear & Eye 8.3.2.1. Drops 8.3.2.2. Lotions 8.3.3. Nasal 8.3.3.1. Drops 8.3.3.2. Sprays 8.3.4. Topical 8.3.4.1. Gel 8.3.4.2. Creams 8.3.5. Parenteral 8.4. Market Attractiveness Analysis By Dosage Form 9. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Application 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) By Application, 2012 to 2022 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Application, 2023 to 2033 9.3.1. Human Medication 9.3.2. Nutraceuticals 9.3.3. Cosmetics 9.3.4. Medical Devices 9.3.5. Veterinary Health 9.4. Market Attractiveness Analysis By Application 10. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By End User 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) By End User, 2012 to 2022 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By End User, 2023 to 2033 10.3.1. CMO/CDMO 10.3.2. Pharmaceutical Companies 10.3.2.1. Human 10.3.2.2. Veterinary 10.3.3. Cosmeceutical Companies 10.3.4. Nutraceutical Companies 10.3.5. Medical Device Manufacturers 10.3.6. Others 10.4. Market Attractiveness Analysis By End User 11. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Region 11.1. Introduction 11.2. Historical Market Size (US$ Million) Analysis By Region, 2012 to 2022 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2023 to 2033 11.3.1. North America 11.3.2. Latin America 11.3.3. Europe 11.3.4. East Asia 11.3.5. South Asia 11.3.6. Oceania 11.3.7. Middle East and Africa (MEA) 11.4. Market Attractiveness Analysis By Region 12. North America Market Analysis 2012 to 2022 and Forecast 2023 to 2033 12.1. Introduction 12.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2012 to 2022 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 12.3.1. By Country 12.3.1.1. U.S. 12.3.1.2. Canada 12.3.2. By Dosage Form 12.3.3. By Application 12.3.4. By End User 12.4. Market Attractiveness Analysis 12.4.1. By Country 12.4.2. By Dosage Form 12.4.3. By Application 12.4.4. By End User 12.5. Market Trends 12.6. Key Market Participants - Intensity Mapping 12.7. Drivers and Restraints - Impact Analysis 12.8. Country Level Analysis & Forecast 12.8.1. U.S. Market Analysis 12.8.1.1. Introduction 12.8.1.2. Market Analysis and Forecast by Market Taxonomy 12.8.1.2.1. By Dosage Form 12.8.1.2.2. By Application 12.8.1.2.3. By End User 12.8.2. Canada Market Analysis 12.8.2.1. Introduction 12.8.2.2. Market Analysis and Forecast by Market Taxonomy 12.8.2.2.1. By Dosage Form 12.8.2.2.2. By Application 12.8.2.2.3. By End User 13. Latin America Market Analysis 2012 to 2022 and Forecast 2023 to 2033 13.1. Introduction 13.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2012 to 2022 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 13.3.1. By Country 13.3.1.1. Mexico 13.3.1.2. Brazil 13.3.1.3. Argentina 13.3.1.4. Rest of Latin America 13.3.2. By Dosage Form 13.3.3. By Application 13.3.4. By End User 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Dosage Form 13.4.3. By Application 13.4.4. By End User 13.5. Market Trends 13.6. Key Market Participants - Intensity Mapping 13.7. Drivers and Restraints - Impact Analysis 13.8. Country Level Analysis & Forecast 13.8.1. Mexico Market Analysis 13.8.1.1. Introduction 13.8.1.2. Market Analysis and Forecast by Market Taxonomy 13.8.1.2.1. By Dosage Form 13.8.1.2.2. By Application 13.8.1.2.3. By End User 13.8.2. Brazil Market Analysis 13.8.2.1. Introduction 13.8.2.2. Market Analysis and Forecast by Market Taxonomy 13.8.2.2.1. By Dosage Form 13.8.2.2.2. By Application 13.8.2.2.3. By End User 13.8.3. Argentina Market Analysis 13.8.3.1. Introduction 13.8.3.2. Market Analysis and Forecast by Market Taxonomy 13.8.3.2.1. By Dosage Form 13.8.3.2.2. By Application 13.8.3.2.3. By End User 14. Europe Market Analysis 2012 to 2022 and Forecast 2023 to 2033 14.1. Introduction 14.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2012 to 2022 14.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 14.3.1. By Country 14.3.1.1. United Kingdom 14.3.1.2. Germany 14.3.1.3. France 14.3.1.4. Italy 14.3.1.5. Spain 14.3.1.6. BENELUX 14.3.1.7. Russia 14.3.1.8. Rest of Europe 14.3.2. By Dosage Form 14.3.3. By Application 14.3.4. By End User 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Dosage Form 14.4.3. By Application 14.4.4. By End User 14.5. Key Market Participants - Intensity Mapping 14.6. Drivers and Restraints - Impact Analysis 14.7. Country Level Analysis & Forecast 14.7.1. The United Kingdom Market Analysis 14.7.1.1. Introduction 14.7.1.2. Market Analysis and Forecast by Market Taxonomy 14.7.1.2.1. By Dosage Form 14.7.1.2.2. By Application 14.7.1.2.3. By End User 14.7.2. Germany Market Analysis 14.7.2.1. Introduction 14.7.2.2. Market Analysis and Forecast by Market Taxonomy 14.7.2.2.1. By Dosage Form 14.7.2.2.2. By Application 14.7.2.2.3. By End User 14.7.3. France Market Analysis 14.7.3.1. Introduction 14.7.3.2. Market Analysis and Forecast by Market Taxonomy 14.7.3.2.1. By Dosage Form 14.7.3.2.2. By Application 14.7.3.2.3. By End User 14.7.4. Italy Market Analysis 14.7.4.1. Introduction 14.7.4.2. Market Analysis and Forecast by Market Taxonomy 14.7.4.2.1. By Dosage Form 14.7.4.2.2. By Application 14.7.4.2.3. By End User 14.7.5. Spain Market Analysis 14.7.5.1. Introduction 14.7.5.2. Market Analysis and Forecast by Market Taxonomy 14.7.5.2.1. By Dosage Form 14.7.5.2.2. By Application 14.7.5.2.3. By End User 14.7.6. BENELUX Market Analysis 14.7.6.1. Introduction 14.7.6.2. Market Analysis and Forecast by Market Taxonomy 14.7.6.2.1. By Dosage Form 14.7.6.2.2. By Application 14.7.6.2.3. By End User 14.7.7. Russia Market Analysis 14.7.7.1. Introduction 14.7.7.2. Market Analysis and Forecast by Market Taxonomy 14.7.7.2.1. By Dosage Form 14.7.7.2.2. By Application 14.7.7.2.3. By End User 15. East Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033 15.1. Introduction 15.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2012 to 2022 15.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 15.3.1. By Country 15.3.1.1. China 15.3.1.2. Japan 15.3.1.3. South Korea 15.3.2. By Dosage Form 15.3.3. By Application 15.3.4. By End User 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Dosage Form 15.4.3. By Application 15.4.4. By End User 15.5. Key Market Participants - Intensity Mapping 15.6. Drivers and Restraints - Impact Analysis 15.7. Country Level Analysis & Forecast 15.7.1. China Market Analysis 15.7.1.1. Introduction 15.7.1.2. Market Analysis and Forecast by Market Taxonomy 15.7.1.2.1. By Dosage Form 15.7.1.2.2. By Application 15.7.1.2.3. By End User 15.7.2. Japan Market Analysis 15.7.2.1. Introduction 15.7.2.2. Market Analysis and Forecast by Market Taxonomy 15.7.2.2.1. By Dosage Form 15.7.2.2.2. By Application 15.7.2.2.3. By End User 15.7.3. South Korea Market Analysis 15.7.3.1. Introduction 15.7.3.2. Market Analysis and Forecast by Market Taxonomy 15.7.3.2.1. By Dosage Form 15.7.3.2.2. By Application 15.7.3.2.3. By End User 16. South Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2012 to 2022 16.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1. India 16.3.1.2. Malaysia 16.3.1.3. Thailand 16.3.1.4. Indonesia 16.3.1.5. Rest of South Asia 16.3.2. By Dosage Form 16.3.3. By Application 16.3.4. By End User 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Dosage Form 16.4.3. By Application 16.4.4. By End User 16.5. Key Market Participants - Intensity Mapping 16.6. Drivers and Restraints - Impact Analysis 16.7. Country Level Analysis & Forecast 16.7.1. India Market Analysis 16.7.1.1. Introduction 16.7.1.2. Market Analysis and Forecast by Market Taxonomy 16.7.1.2.1. By Dosage Form 16.7.1.2.2. By Application 16.7.1.2.3. By End User 16.7.2. Malaysia Market Analysis 16.7.2.1. Introduction 16.7.2.2. Market Analysis and Forecast by Market Taxonomy 16.7.2.2.1. By Dosage Form 16.7.2.2.2. By Application 16.7.2.2.3. By End User 16.7.3. Thailand Market Analysis 16.7.3.1. Introduction 16.7.3.2. Market Analysis and Forecast by Market Taxonomy 16.7.3.2.1. By Dosage Form 16.7.3.2.2. By Application 16.7.3.2.3. By End User 16.7.4. Indonesia Market Analysis 16.7.4.1. Introduction 16.7.4.2. Market Analysis and Forecast by Market Taxonomy 16.7.4.2.1. By Dosage Form 16.7.4.2.2. By Application 16.7.4.2.3. By End User 17. Oceania Market 2012 to 2022 and Forecast 2023 to 2033 17.1. Introduction 17.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2012 to 2022 17.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 17.3.1. By Country 17.3.1.1. Australia 17.3.1.2. New Zealand 17.3.2. By Dosage Form 17.3.3. By Application 17.3.4. By End User 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Dosage Form 17.4.3. By Application 17.4.4. By End User 17.5. Key Market Participants - Intensity Mapping 17.6. Drivers and Restraints - Impact Analysis 17.7. Country Level Analysis & Forecast 17.7.1. Australia Market Analysis 17.7.1.1. Introduction 17.7.1.2. Market Analysis and Forecast by Market Taxonomy 17.7.1.2.1. By Dosage Form 17.7.1.2.2. By Application 17.7.1.2.3. By End User 17.7.2. New Zealand Market Analysis 17.7.2.1. Introduction 17.7.2.2. Market Analysis and Forecast by Market Taxonomy 17.7.2.2.1. By Dosage Form 17.7.2.2.2. By Application 17.7.2.2.3. By End User 18. Middle East and Africa (MEA) Market Analysis 2012 to 2022 and Forecast 2023 to 2033 18.1. Introduction 18.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2012 to 2022 18.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 18.3.1. By Country 18.3.1.1. GCC Countries 18.3.1.2. Türkiye 18.3.1.3. South Africa 18.3.1.4. Rest of Middle East and Africa 18.3.2. By Dosage Form 18.3.3. By Application 18.3.4. By End User 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Dosage Form 18.4.3. By Application 18.4.4. By End User 18.5. Key Market Participants - Intensity Mapping 18.6. Drivers and Restraints - Impact Analysis 18.7. Country Level Analysis & Forecast 18.7.1. GCC Countries Market Analysis 18.7.1.1. Introduction 18.7.1.2. Market Analysis and Forecast by Market Taxonomy 18.7.1.2.1. By Dosage Form 18.7.1.2.2. By Application 18.7.1.2.3. By End User 18.7.2. Türkiye Market Analysis 18.7.2.1. Introduction 18.7.2.2. Market Analysis and Forecast by Market Taxonomy 18.7.2.2.1. By Dosage Form 18.7.2.2.2. By Application 18.7.2.2.3. By End User 18.7.3. South Africa Market Analysis 18.7.3.1. Introduction 18.7.3.2. Market Analysis and Forecast by Market Taxonomy 18.7.3.2.1. By Dosage Form 18.7.3.2.2. By Application 18.7.3.2.3. By End User 19. Market Structure Analysis 19.1. Market Analysis by Tier of Companies 19.2. Market Share Analysis of Top Players (%) 19.3. Market Presence Analysis 19.3.1. By Regional Footprint of Players 19.3.2. Product Footprint of Players 19.3.3. Channel Footprint of Players 20. Competition Analysis 20.1. Competition Dashboard 20.2. Competition Benchmarking 20.3. Competition Deep Dive 20.3.1. AbbVie Pharmaceutical Contract Manufacturing 20.3.1.1. Overview 20.3.1.2. Product Portfolio 20.3.1.3. Key Financials 20.3.1.4. SWOT Analysis 20.3.1.5. Key Developments 20.3.1.6. Sales Footprint 20.3.1.7. Strategy Overview 20.3.1.7.1. Marketing Strategies 20.3.1.7.2. Product Strategies 20.3.1.7.3. Channel Strategies 20.3.2. Aenova Group 20.3.2.1. Overview 20.3.2.2. Product Portfolio 20.3.2.3. Key Financials 20.3.2.4. SWOT Analysis 20.3.2.5. Key Developments 20.3.2.6. Sales Footprint 20.3.2.7. Strategy Overview 20.3.2.7.1. Marketing Strategies 20.3.2.7.2. Product Strategies 20.3.2.7.3. Channel Strategies 20.3.3. APPCO Pharmaceutical Corporation 20.3.3.1. Overview 20.3.3.2. Product Portfolio 20.3.3.3. Key Financials 20.3.3.4. SWOT Analysis 20.3.3.5. Key Developments 20.3.3.6. Sales Footprint 20.3.3.7. Strategy Overview 20.3.3.7.1. Marketing Strategies 20.3.3.7.2. Product Strategies 20.3.3.7.3. Channel Strategies 20.3.4. Atral Pharmaceutical 20.3.4.1. Overview 20.3.4.2. Product Portfolio 20.3.4.3. Key Financials 20.3.4.4. SWOT Analysis 20.3.4.5. Key Developments 20.3.4.6. Sales Footprint 20.3.4.7. Strategy Overview 20.3.4.7.1. Marketing Strategies 20.3.4.7.2. Product Strategies 20.3.4.7.3. Channel Strategies 20.3.5. Aurigene Pharmaceutical Services (Dr. Reddy’s) 20.3.5.1. Overview 20.3.5.2. Product Portfolio 20.3.5.3. Key Financials 20.3.5.4. SWOT Analysis 20.3.5.5. Key Developments 20.3.5.6. Sales Footprint 20.3.5.7. Strategy Overview 20.3.5.7.1. Marketing Strategies 20.3.5.7.2. Product Strategies 20.3.5.7.3. Channel Strategies 20.3.6. Biological E. Ltd. 20.3.6.1. Overview 20.3.6.2. Product Portfolio 20.3.6.3. Key Financials 20.3.6.4. SWOT Analysis 20.3.6.5. Key Developments 20.3.6.6. Sales Footprint 20.3.6.7. Strategy Overview 20.3.6.7.1. Marketing Strategies 20.3.6.7.2. Product Strategies 20.3.6.7.3. Channel Strategies 20.3.7. BioPlus Life Sciences 20.3.7.1. Overview 20.3.7.2. Product Portfolio 20.3.7.3. Key Financials 20.3.7.4. SWOT Analysis 20.3.7.5. Key Developments 20.3.7.6. Sales Footprint 20.3.7.7. Strategy Overview 20.3.7.7.1. Marketing Strategies 20.3.7.7.2. Product Strategies 20.3.7.7.3. Channel Strategies 20.3.8. Bora Pharmaceuticals 20.3.8.1. Overview 20.3.8.2. Product Portfolio 20.3.8.3. Key Financials 20.3.8.4. SWOT Analysis 20.3.8.5. Key Developments 20.3.8.6. Sales Footprint 20.3.8.7. Strategy Overview 20.3.8.7.1. Marketing Strategies 20.3.8.7.2. Product Strategies 20.3.8.7.3. Channel Strategies 20.3.9. Cambrex Corporation 20.3.9.1. Overview 20.3.9.2. Product Portfolio 20.3.9.3. Key Financials 20.3.9.4. SWOT Analysis 20.3.9.5. Key Developments 20.3.9.6. Sales Footprint 20.3.9.7. Strategy Overview 20.3.9.7.1. Marketing Strategies 20.3.9.7.2. Product Strategies 20.3.9.7.3. Channel Strategies 20.3.10. COC Farmaceutici 20.3.10.1. Overview 20.3.10.2. Product Portfolio 20.3.10.3. Key Financials 20.3.10.4. SWOT Analysis 20.3.10.5. Key Developments 20.3.10.6. Sales Footprint 20.3.10.7. Strategy Overview 20.3.10.7.1. Marketing Strategies 20.3.10.7.2. Product Strategies 20.3.10.7.3. Channel Strategies 20.3.11. Contract Pharmaceuticals Limited (CPL) 20.3.11.1. Overview 20.3.11.2. Product Portfolio 20.3.11.3. Key Financials 20.3.11.4. SWOT Analysis 20.3.11.5. Key Developments 20.3.11.6. Sales Footprint 20.3.11.7. Strategy Overview 20.3.11.7.1. Marketing Strategies 20.3.11.7.2. Product Strategies 20.3.11.7.3. Channel Strategies 20.3.12. DPT Laboratories, Ltd. 20.3.12.1. Overview 20.3.12.2. Product Portfolio 20.3.12.3. Key Financials 20.3.12.4. SWOT Analysis 20.3.12.5. Key Developments 20.3.12.6. Sales Footprint 20.3.12.7. Strategy Overview 20.3.12.7.1. Marketing Strategies 20.3.12.7.2. Product Strategies 20.3.12.7.3. Channel Strategies 20.3.13. Eurofins 20.3.13.1. Overview 20.3.13.2. Product Portfolio 20.3.13.3. Key Financials 20.3.13.4. SWOT Analysis 20.3.13.5. Key Developments 20.3.13.6. Sales Footprint 20.3.13.7. Strategy Overview 20.3.13.7.1. Marketing Strategies 20.3.13.7.2. Product Strategies 20.3.13.7.3. Channel Strategies 20.3.14. JGL d.d. 20.3.14.1. Overview 20.3.14.2. Product Portfolio 20.3.14.3. Key Financials 20.3.14.4. SWOT Analysis 20.3.14.5. Key Developments 20.3.14.6. Sales Footprint 20.3.14.7. Strategy Overview 20.3.14.7.1. Marketing Strategies 20.3.14.7.2. Product Strategies 20.3.14.7.3. Channel Strategies 20.3.15. Mikart 20.3.15.1. Overview 20.3.15.2. Product Portfolio 20.3.15.3. Key Financials 20.3.15.4. SWOT Analysis 20.3.15.5. Key Developments 20.3.15.6. Sales Footprint 20.3.15.7. Strategy Overview 20.3.15.7.1. Marketing Strategies 20.3.15.7.2. Product Strategies 20.3.15.7.3. Channel Strategies 20.3.16. PharmaVision (Vizyon Holding) 20.3.16.1. Overview 20.3.16.2. Product Portfolio 20.3.16.3. Key Financials 20.3.16.4. SWOT Analysis 20.3.16.5. Key Developments 20.3.16.6. Sales Footprint 20.3.16.7. Strategy Overview 20.3.16.7.1. Marketing Strategies 20.3.16.7.2. Product Strategies 20.3.16.7.3. Channel Strategies 20.3.17. Pierre Fabre 20.3.17.1. Overview 20.3.17.2. Product Portfolio 20.3.17.3. Key Financials 20.3.17.4. SWOT Analysis 20.3.17.5. Key Developments 20.3.17.6. Sales Footprint 20.3.17.7. Strategy Overview 20.3.17.7.1. Marketing Strategies 20.3.17.7.2. Product Strategies 20.3.17.7.3. Channel Strategies 20.3.18. TriRx Pharmaceutical Services 20.3.18.1. Overview 20.3.18.2. Product Portfolio 20.3.18.3. Key Financials 20.3.18.4. SWOT Analysis 20.3.18.5. Key Developments 20.3.18.6. Sales Footprint 20.3.18.7. Strategy Overview 20.3.18.7.1. Marketing Strategies 20.3.18.7.2. Product Strategies 20.3.18.7.3. Channel Strategies 20.3.19. UI Pharmaceuticals 20.3.19.1. Overview 20.3.19.2. Product Portfolio 20.3.19.3. Key Financials 20.3.19.4. SWOT Analysis 20.3.19.5. Key Developments 20.3.19.6. Sales Footprint 20.3.19.7. Strategy Overview 20.3.19.7.1. Marketing Strategies 20.3.19.7.2. Product Strategies 20.3.19.7.3. Channel Strategies 20.3.20. Wasdell Group 20.3.20.1. Overview 20.3.20.2. Product Portfolio 20.3.20.3. Key Financials 20.3.20.4. SWOT Analysis 20.3.20.5. Key Developments 20.3.20.6. Sales Footprint 20.3.20.7. Strategy Overview 20.3.20.7.1. Marketing Strategies 20.3.20.7.2. Product Strategies 20.3.20.7.3. Channel Strategies 20.3.21. Aphena Pharma 20.3.21.1. Overview 20.3.21.2. Product Portfolio 20.3.21.3. Key Financials 20.3.21.4. SWOT Analysis 20.3.21.5. Key Developments 20.3.21.6. Sales Footprint 20.3.21.7. Strategy Overview 20.3.21.7.1. Marketing Strategies 20.3.21.7.2. Product Strategies 20.3.21.7.3. Channel Strategies 20.3.22. Syngene International 20.3.22.1. Overview 20.3.22.2. Product Portfolio 20.3.22.3. Key Financials 20.3.22.4. SWOT Analysis 20.3.22.5. Key Developments 20.3.22.6. Sales Footprint 20.3.22.7. Strategy Overview 20.3.22.7.1. Marketing Strategies 20.3.22.7.2. Product Strategies 20.3.22.7.3. Channel Strategies 21. Assumptions and Acronyms Used 22. Research Methodology
Healthcare
July 2017
REP-GB-2782
March 2024
315 pages
Explore Healthcare Insights
View Reports
Non-Sterile Liquids/Suspensions Market
